Metabolic dysfunction-associated steatohepatitis (MASH) is often referred to as a “silent disease,” as it typically shows no signs of symptoms in early stages. But it can come with certain ...

If you have obesity, losing even a little weight helps not only improve your overall health, but also prevent liver issues ...

Recent research suggests that a new approach could help even patients with advanced forms of fatty liver disease.

about 14 percent may be candidates for MASH treatment, which is currently indicated for liver fibrosis stages 2 and 3 (fibrosis is staged from 0 [none] to 4 [cirrhosis]). Type 2 diabetes is ...

Distinguishing the stages of fibrosis The presence of comorbidities like obesity, diabetes, and hypertension, and their significant overlap with MASH creates challenges with clinical study design ...

More than 50% of patients in each dose cohort also saw a 1-stage or greater improvement in fibrosis without worsening of MASH, a key secondary endpoint, compared to 33% of the placebo group.

However, where it fell short was with respect to the failure at week 36 with the phase 2b SYMMETRY study, which used EFX to treat compensated cirrhosis patients due to MASH stage F4 fibrosis.

The Phase 2 test of the Akero drug, efruxifermin (EFX), was designed with a main goal of showing improvement by one stage of fibrosis or more with no worsening of other measures of MASH after 96 ...

Inc. (NASDAQ:ETNB), with a market capitalization of $1.14 billion, is a clinical-stage biopharmaceutical company focusing on the development of innovative therapies for the treatment of liver and ...

Both MASH studies are currently enrolling patients ... MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in conjunction with diet and exercise.